Biotherapeutic product characterization to support ... · Biotherapeutic product characterization to support accelerated process development Kyle Zingaro, Ph.D. Alexion Pharmaceuticals

Biotherapeutic product characterization to support accelerated process development

Kyle Zingaro, Ph.D.

Alexion Pharmaceuticals

2015 Biomanufacturing Technology Summit

June 25, 2015

Alexion is focused on developing life-transforming treatments for patients with severe and life-threatening diseases

2

Our Mission: Treating Patients with Severe & Devastating Diseases

Life-Threatening

Devastating

Transformative Clinical Benefit

No Effective Treatments

Severe

3

Sydney, Australia Asia-Pacific Regional HQ Country Operations

Mumbai, India Global Business Services

Shanghai, China Country Operations

Tokyo, Japan Japan Regional HQCountry Operations

Toronto, Canada Country Operations

Cambridge, MATranslational Medicine Group

Cheshire, CT Global Headquarters North America Regional HQ

Smithfield, RI Manufacturing Operations

Washington DCGlobal Government Affairs

Stockholm, SwedenNordic Country Operations

Barcelona, Spain Country Operations

Milan, ItalyCountry Operations

Munich, GermanyCountry Operations

Paris, FranceEuropean Service CenterCountry Operations

Brussels, BelgiumGovernment Affairs, EMEACountry Operations

London, UK Country Operations

Dublin, Ireland Global Supply Chain and Distribution

Buenos Aires, ArgentinaCountry Operations

São Paulo, Brazil Country Operations

Mexico City, Mexico Country Operations

Bogotá, ColombiaCountry Operations

Miami, FL Latin America Regional HQ

Dubai, UAEMiddle East OperationsCountry Operations

Moscow, Russia Country Operations

Lausanne, SwitzerlandEMEA Operations CenterCountry Operations

Istanbul, TurkeyCountry Operations

Our Global Footprint~2,400 dedicated employees serving patients in almost 50 countries

Biologic Process DevelopmentConnecting process inputs with product output

5

Development of a Biologic Manufacturing Process

“The aim of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the

intended performance of the product.”

-ICH Guideline Q8 (R2)

6

Process Development Goals• Definition and characterization of a robust process to

generate quality therapeutic products

• Assessment of risk in design of new processes and change to existing processes

• Implementation of new technologies to improve those processes

• Support of clinical and commercial manufacturing efforts

Analytical Method Lifecycle Roadmap

8

Development and Characterization:Who supports whom?

• Clone selection, process definition, and process changes can not happen without analytical data

• Analytical methods exist to support manufacturing process definition and operation

http://programmedevelopment.com/what-is-ability-/ability-and-methods

Defining a “Biologic Fingerprint”What level of characterization defines a product?

10

Critical Quality Attributes (CQA)

“A CQA is a physical, chemical, biological, or microbiological property…that should be within an appropriate limit, range, or

distribution to ensure the desired product quality.”

-ICH Q8 (R2)

Biologics Include primary, secondary, tertiary, and quaternary protein structure and post-translational modifications

11

A Biological Fingerprint• Primary and higher order structure with post-

translational and chemical modifications which uniquely describe a protein

• Fingerprint-like: “integrated, multi-parameter approaches that are extremely sensitive in identifying analytical differences”1

• No clear consensus definition

• Challenged by constantly evolving analytical methods

https://www.mdsp.org/Organization/FieldOperationsBureau/Barracks/BarrackNRockville/FingerprintingServices.aspx

1Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, FDA Guidance for Industry, 2014

12

Biologic Fingerprints & Innovator Companies• Clearer connections between biophysical quality and clinical

safety and efficacy

• Development of robust processes requires an understanding of the impact of process inputs on the biologic fingerprint

• Implementation of process changes require demonstration of comparability in critical quality attributes

13

Approval of Zarxio (Neupogen Biosimilar)• methionyl-Granulocyte Colony Stimulating Factor (G-CSF)

http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428780.pdf

Clinical Phase Relevant Testing & CharacterizationHow much do we learn as a product & process develop?

15

When do we really need to know all that?

• Process improvement and optimization is completed throughout clinical development timeframes

• Process knowledge is expected to be limited for early filings

• Complete information must be available for commercial filing

Phase 1 Phase 2 Phase 3 Approval Commercial Product

16

Product Safety and Efficacy Studies• Different phases of clinical trials require different standards:

○ Phase 1 (Safety) – Simple efficacy assay (eg. ELISA), limited method understanding, and method qualification

○ Phase 3 (Efficacy) – Established and well characterized methods, method validation, cell-based efficacy assays

• Method understanding improves throughout development process

17

Process Changes• Manufacturing process changes will happen!○ Clinical Manufacturing vs. Commercial Manufacturing

• Changes must produce “highly similar” material

• Clinical Development○ Significant Changes

• Approved Application○ Major, Moderate, or Minor Changes

Accelerated Process Development Faster from clinic to market

19

Why do we need to develop processes faster?

• Patient Benefit○ Provide beneficial therapies to patients faster

• Regulatory Changes○ Breakthrough designation shortens clinical and CMC

timelines

• Commercial Benefits

20

Isn’t faster a good thing?• All stages of process and method development still need to

be completed

• We have less time to develop and less time to respond to regulatory inquiries

• How can we get it all done?

Strategies for Faster CMC DevelopmentReconciling shorter timelines and better characterization

22

Management Strategies

• Detailed Quality Target Product Profile (QTPP)

• Cross-Functional Communication

• Clinical and CMC Collaboration

• Strategic Planning

• Templates

23

Technical Strategies• Predictive Modeling

○ Process and product predictions throughout development and product lifecycle

• Real Time Monitoring

○ More data produced at and online

• Platform Processes

Platform ProcessesDefining an evolving standard

25

“Data derived from relevant prior knowledge, including platform manufacturing, …can be leveraged to support development of the commercial process and expedite

scientific understanding.”

-ICH Guideline Q11

Why do we need a platform?

Cell Bank

Seed Train

Production BioreactorPurification

Quality Analytics

26

What makes a “good” platform?

• Quality

• Robustness

• Raw Material Supply Chain

• Scalability

• Productivity

• Cost Effective

27

Why do we change a platform process?• Technology Continues to Evolve○ Quality

○ Robustness

○ Productivity

• Patient Safety○ Removal of animal derived

components

• Raw Materials Biomanufacturing Flexibility, Bio-G, Bioproduction Group, http://www.bio-g.com/whitepapers/download/3

28

How & when do we change a platform process?• Incremental improvement can be identified but are difficult to

implement

• Step-wise improvements when sufficient progress has been made in a new platform

○ What is the clinical or commercial need?

• Platform qualification evaluations using our biologic fingerprint

○ How close is close enough?

Conclusions and Future Challenges

30

Conclusions• Process development timelines are always shortening

• CMC development efforts including process and method development need to keep pace

• Both method and process should be expected to evolve to meet the clinical and commercial applications of a product

31

Future Challenges• Analytical and manufacturing technologies continue to evolve

• Standards and expectations will evolve with those technologies

• Timelines will always be shortened where possible while the expectations do not change

• Organization, communication, and efficient management are required to meet those expectations

32

Acknowledgements

• Process Development

○ Pratik Jaluria

○ Hunter Malanson

○ Matt Rimbey

○ Ina Alickolli

○ Krishanu Mathur

○ Loray Paul

○ Luke Loftus

• Analytical Sciences○ Zhenyu Gu & Jack Yu

• Product Characterization○ Adriana Kita